Abstract
Osteoporosis (OP) and osteoarthritis (OA) are clinically common chronic orthopedic diseases. With the aging of the global population, OP and OA pose a serious threat to human health. Exosomes are nanoscale vesicles secreted by cells and can mediate inter-cell communication. Recent research has shown that plant-derived exosomes-like nanovesicles (PELNs) can affect the proliferation and differentiation of osteoclasts, osteoblasts, bone marrow mesenchymal stem cells (BMSCs) and chondrocytes, regulate the immune system and inhibit inflammatory responses, and have potential value in treating OP and OA. This article summarizes the basic concepts, formation and components, separation and characterization methods of PELNs, and focuses on discussing the impact of PELNs on OP and OA, aiming to provide new ideas for the research of OP and OA.
Keywords: Plant deprivative, exosome-like nanovesicles, osteoporosis, osteoarthritis, bone
1. Introduction
Osteoporosis is characterized by a reduction in bone mass, deterioration of microarchitecture, and increased fracture risk [1–3]. Epidemiological data indicate that osteoporosis affects one in three women and one in five men aged over 50, posing lifelong health burdens [4]. Osteoarthritis, the most prevalent form of arthritis among adults, is marked by chronic pain and loss of mobility. Its incidence significantly increases with age, particularly after the age of 40 [5]. Current OP management combines pharmacological interventions with adjunctive strategies: weight-bearing exercise and calcium/vitamin D supplementation remain foundational non-pharmacological approaches [6]. Conventional therapeutic agents include bisphosphonates, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), and calcitonin. In recent years, emerging pharmacological options such as fluoride compounds, parathyroid hormone analogs, and prostaglandin E2 derivatives have been introduced into clinical practice. Recent studies have further demonstrated the therapeutic potential of plant-derived exosome vesicles in osteoporosis management through modulation of bone metabolic homeostasis [7]. Exosomes are spherical nanovesicles, ranging from 30 to 100 nanometers in diameter, that are secreted by cells into the extracellular environment, facilitating intercellular communication [8–11] and the transport of biomolecules [12–15]. Previous exosome studies have focused on exosomes of animal cell origin, and in recent years, exosomes of plant origin have gradually been emphasized [14,16]. As a natural component, plant-derived exosome-like nanovesicles (PELNs) have been shown to possess structural and functional similarities to their mammalian counterparts [17]. Plant-derived exosome-like nanovesicles (PELNs) are more accessible and easier to produce at scale compared to animal exosomes. Due to their distinctive physiological, chemical, and biological properties, PELNs have significant potential for applications in disease therapy and the development of nanocarrier drug delivery systems (DDS) capable of delivering varying dosages [18–21]. Recent studies suggest that PELNs may hold promise for the treatment of osteoporosis and osteoarthritis through mechanisms involving the regulation of bone metabolism, reduction of chronic inflammation, and promotion of cartilage regeneration. In this review, we summarize the research advancements regarding the role of plant-derived exosome-like nanovesicles in the modulation of osteoporosis and osteoarthritis, aiming to provide novel insights for both clinical and fundamental research in these areas (Figure 1).
Figure 1.
Schematic illustration of plant-derived exosome-like nanovesicles (PELNs) in osteoporosis and osteoarthritis regulation.
PELNs modulate bone metabolism by inhibiting osteoclast differentiation via suppression of RANKL signaling pathways and promoting osteoblast proliferation/differentiation through BMP-2/Smad/RUNX2 pathways. In osteoporosis, PELNs enhance osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduce oxidative stress. For osteoarthritis, PELNs attenuate inflammation by inhibiting NF-κB activation and pro-inflammatory cytokines (e.g., TNF-α, IL-6), while promoting cartilage regeneration via delivery of growth factors and metabolic support to chondrocytes. Created with BioRender.com.
2. Biogenesis and components of exosome-like nanovesicles of plant origin
2.1. Biogenesis of PELNs
Current studies have identified three potential pathways for the biogenesis of plant-derived exosome-like nanovesicles (PELNs): the EXPO (exocyst-positive organelle) pathway, the multivesicular bodies (MVBs) pathway, and the vesicular pathway [22]. Among these, the MVBs pathway has been shown to closely resemble the biogenesis pathway of mammalian-derived exosomes and is the primary route for the formation of PELNs. The basic process involves the invagination and budding of the cytoplasmic membrane to form early endosomes, which further invaginate and mature into late endosomes that communicate with the Golgi network. Within these late endosomes, intraluminal vesicles (ILVs) containing cytoplasmic components, DNA, RNA, and lipids are formed. These ILVs are then transformed into ILV-containing MVBs, which are released into the extracellular space through fusion with the cytoplasmic membrane, thereby releasing ILVs into the extracellular environment to form PELNs [23]. The EXPO pathway refers to the intracellular formation of EXPOs with a double-membrane structure similar to that of autophagosomes; these EXPOs fuse with the plasma membrane and release single-membrane extracellular vesicles into the cell wall [24]. The vesicular pathway involves the fusion of cytosolic ILVs with the cytoplasmic membrane, resulting in the formation of vesicles that are released into the extracellular space [25].
2.2. Components of PELNs
The composition of plant-derived exosome-like nanovesicles (PELNs) is complex and influenced by various factors, including plant species and environmental conditions, encompassing multiple types of biomolecules [26,27]. These biomolecules primarily include: 1. Lipid bilayer [28]: The outer structure of PELNs consists of a lipid bilayer, which represents the fundamental structural feature. This lipid bilayer contains various lipids, such as phosphatidic acid, phosphatidic acid diamide, and phosphatidylcholine. These lipids and lipid assemblies may function as signals that facilitate preferential uptake by different receptor cells; 2. Proteins: The protein composition includes membrane proteins, cytoplasmic proteins, and specific proteins. Some studies suggest that membrane proteins may play a role in enhancing the uptake and internalization of PELNs by mammalian cells; however, there is a lack of evidence linking these proteins to the intrinsic therapeutic activity of PELNs; 3. Nucleic acids [29]: PELNs may contain various types of RNA, such as microRNAs (miRNAs) and small RNAs (sRNAs), which could be involved in regulating gene expression across species; 4. Metabolites and small molecule compounds: PELNs may include a range of metabolites and small molecule compounds that reflect the metabolic state of plant cells and may play a role in intercellular communication by transmitting signals.
3. Isolation and characterization of plant-derived exosome-like nanovesicles
The isolation of plant-derived exosome-like nanovesicles (PELNs) primarily relies on techniques such as ultracentrifugation [30], polymer precipitation [31], and size-exclusion chromatography [32]. Ultracentrifugation, currently the most widely standardized method, employs gradient centrifugation to remove impurities and enrich PELNs [33]. Polymer precipitation (e.g. using polyethylene glycol) achieves rapid sedimentation by competitively binding water molecules, offering advantages of operational simplicity and high-throughput capability [34]. Emerging technologies, including hydrophobic chromatography based on capillary-channeled polymer fibers, enable efficient isolation of PELNs from diverse fruits and vegetables, yielding 2.3 × 10^9 to 8.0 × 10^10 particles/mL [35,36]. Zhao et al. [37] have recently developed an enzymatic plant cell wall degradation-based method for extracellular vesicle (EV) isolation, which has been successfully applied to extract EVs from Morinda officinalis roots. This innovative approach demonstrates enhanced EV yield with significantly reduced contamination from intracellular components compared to conventional extraction techniques.
For characterization, transmission electron microscopy (TEM) reveals that PELNs typically exhibit spherical or cup-shaped morphologies, with particle sizes ranging from 40 to 200 nm. Their colloidal stability is supported by a negatively distributed zeta potential (approximately −30 mV) [38]. Chemical analyses, guided by the MISEV guidelines [39], validate vesicle integrity through detection of marker proteins such as heat shock protein 70 (HSP70) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [40]. Lipidomic studies highlight the biological roles of membrane components like phosphatidic acid (PA) and phosphatidylcholine (PC) [41], while RNA sequencing identifies PELNs-derived miRNAs (e.g. from Panax notoginseng) capable of modulating 4,010 human genes [42].
The choice of isolation methods significantly impacts vesicle size, surface charge, and bioactivity [43]. To enhance purity, combinatorial approaches (e.g. ultracentrifugation coupled with size-exclusion chromatography) are often employed [44].
4. PELNs play a role in regulating bone metabolism
Osteoporosis (OP) is a systemic bone metabolism disorder characterized by an increased risk of fragility fractures, which can lead to pain, functional impairment, and even mortality. Clinical pharmacological treatments for osteoporosis primarily include foundational bone metabolism supplements (e.g. calcium and vitamin D), bone resorption inhibitors (e.g. bisphosphonates, calcitonin), and bone formation enhancers (e.g. parathyroid hormone analogs) [45]. Mesenchymal stem cell (MSC)-derived exosomes modulate the immune system to regulate osteoclasts, osteoblasts, and osteoimmune processes [46]. For example: Adipose-derived MSC (ADSC) exosomes inhibit the NLRP3 inflammasome in osteoclasts of diabetic osteoporosis (OP) rat models and increase bone mineral density (BMD) [47]; MSC-derived exosomes enhance osteogenic differentiation of bone marrow-derived MSCs by suppressing M1 macrophage polarization and reducing levels of pro-inflammatory cytokines (e.g. IL-1β and IL-6) [48]. Although these medications demonstrate significant efficacy in reducing bone loss, increasing bone density, and lowering the incidence of osteoporotic fractures, they are also associated with certain adverse effects [49,50]. Recent studies have indicated that plant-derived extracellular nanovesicles (PELNs) can regulate bone metabolism and hold potential value for the treatment of osteoporosis, warranting closer attention (Figure 2).
Figure 2.
The regulatory role of PELNs on cells in bone metabolism.
4.1. PELNs inhibit osteoclast differentiation
An increased number of osteoclasts and enhanced bone resorption are important pathological mechanisms underlying the development of osteoporosis. Receptor activator of nuclear factor κB ligand (RANKL) is a key regulator of osteoclast maturation; it binds to the RANK receptor on osteoclast precursor cells to promote their differentiation [51–53]. Seo et al. [54] employed sucrose gradient centrifugation to isolate ginseng-derived extracellular nanovesicles (PELNs), which were found to contain high concentrations of the ginsenosides Rb1 and Rg1. Further studies revealed that ginseng-derived PELNs could inhibit RANKL-mediated signaling pathways and gene expression associated with osteoclast differentiation. Moreover, in animal experiments, these PELNs alleviated bone loss and improved bone microarchitecture in osteoporotic mice. Nanovesicles derived from plums also demonstrated the ability to enhance osteoblast differentiation while suppressing osteoclast activation [55].
4.2. PELNs promote the proliferation and differentiation of osteoblasts
Osteoblasts are regulated by various cytokines, and their primary function is the synthesis and mineralization of the bone matrix. Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor-β superfamily, plays a crucial role in bone remodeling during adulthood. It promotes osteogenesis by binding to specific receptors and activating signaling pathways in osteoblasts [56]. Hwang et al. [57] found that yam-derived extracellular nanovesicles (PELNs) increased the gene expression of BMP-2 and stimulated the proliferation and differentiation of osteoblasts through the activation of the BMP-2/p-p38-dependent Runt-related transcription factor 2 (RUNX2) pathway. Similarly, a study by Sim et al. [58] demonstrated that apple-derived PELNs enhanced the expression of genes associated with osteoblast growth and differentiation, promoting osteogenesis by regulating the BMP2/Smad1 pathway. Furthermore, research by Park et al. [55] evealed that plum-derived PELNs exert bidirectional regulatory effects on bone, inhibiting osteoclast activity while promoting osteoblast differentiation. A recent study by Cao et al. [59] has demonstrated that MOEVLPs (Morinda officinalis-derived extracellular vesicle-like particles) significantly enhance proliferation of murine MC3T3-E1 cells (embryonic osteoprogenitor cells) and stimulate osteogenic activity, thereby promoting bone formation.
4.3. PELNs induce osteogenic differentiation of bone marrow MSCs
Bone marrow mesenchymal stem cells (BMSCs) are a class of pluripotent stem cells capable of differentiating into osteoblasts, adipocytes, chondrocytes, and other cell types [60]. It has been demonstrated that altered proliferation and differentiation of BMSCs serve as a primary cause of senile osteoporosis [61]. Furthermore, recent evidence indicates that cellular senescence of BMSCs also contributes to the development of senile osteoporosis [62,63]. The reduced osteogenic differentiation of BMSCs represents a crucial pathogenic mechanism underlying osteoporosis [64]. Zhao et al. [65] employed differential ultracentrifugation to extract PELNs and found that these vesicles could promote the osteogenic differentiation of BMSCs via the estrogen receptor α signaling pathway. Zhan et al. [66] reported that Clostridium perfringens in the feces of postmenopausal osteoporotic patients produces trimethylamine-N-oxide (TMAO), which inhibits the osteogenic differentiation of BMSCs as identified through sequencing. PELNs derived from Pueraria lobata can enhance the osteogenic differentiation of BMSCs by degrading TMAO. In vitro animal studies have further validated that Pueraria Mirifica-derived PELNs exhibit superior anti-osteoporotic effects. Oxidative stress is a significant pathological mechanism in the progression of osteoporosis, as it inhibits the proliferative capacity of BMSCs and results in decreased osteogenic differentiation alongside increased lipogenic differentiation of these cells. A study by Perut [67] found that strawberry-derived PELNs are rich in vitamin C, which mitigates oxidative stress and promotes the proliferation of BMSCs. Conversely, Gupta et al. [68] discovered that PELNs sourced from white powdery vine improved the oxidative stress status of BMSCs, enhanced their proliferation, and bolstered their osteogenic differentiation (Table 1).
Table 1.
Recent advances and potential applications of plant-derived exosome-like nanoparticles (PELNs) in osteoporosis and osteoarthritis.
| Author (Year) | Plant source | Disease model | Key findings | Proposed mechanism |
|---|---|---|---|---|
| Section 4: Osteoporosis | Osteoporosis | |||
| Seo et al. (2023) | Ginseng | OP | Inhibited RANKL-mediated osteoclast differentiation; reduced bone loss in mice | Contains ginsenosides Rb1/Rg1; suppresses RANKL signaling pathways |
| Park et al. (2023) | Plum | OP | Enhanced osteoblast differentiation; suppressed osteoclast activation | Promotes BMP-2 expression and osteogenic markers (RUNX2, ALP, OCN) |
| Sim et al. (2023) | Apple | OP | Increased osteoblast differentiation and mineralization | Upregulated BMP-2/Smad1 pathway |
| Zhao et al. (2024) | Rhizoma Drynariae | OP | Reversed osteoporosis by enhancing osteogenic differentiation of BMSCs | Targeted ERα signaling pathway |
| Zhan et al. (2023) | Pueraria lobata (kudzu) | OP | Alleviated osteoporosis by enhancing autophagy in BMSCs | Activated autophagy via AMPK/mTOR pathway |
| Gupta et al. (2023) | Cissus quadrangularis | OP | Promoted osteogenic differentiation of BMSCs | Increased ALP activity and calcium deposition |
| Cao et al.(2024) | Morinda | OP | enhance proliferation of murine MC3T3-E1 cells | stimulate osteogenic activity, thereby promoting bone formation |
| Section 5: Osteoarthritis | Osteoarthritis | |||
| Kim (2023) | Ginseng | OA | Reduced TNF-α and IL-6 levels; anti-inflammatory effects | Inhibited NF-κB activation |
| Zhu et al. (2023) | Garlic | OA/Colitis | Protected cartilage by modulating immune response | Suppressed TLR4/MyD88/NF-κB pathway |
| Yıldırım et al. (2024) | Tomato | OA | Enhanced chondrocyte markers (ACAN, SOX9, COMP); promoted cartilage regeneration | Delivered growth factors to chondrocytes |
| Chen et al. (2022) | Spinach | OA | Improved cartilage homeostasis under light exposure | Increased ATP/NADPH levels; enhanced chondrocyte anabolism |
| Qiu et al. (2020) | Curcumin (turmeric) | OA | Attenuated cartilage degradation and inflammation | Modulated miR-124/NF-κB and miR-143/ROCK1/TLR9 pathways |
| Perut et al. (2021) | Strawberry | OA | Protected chondrocytes from oxidative stress | Reduced ROS production; enhanced antioxidant defenses |
This table compiles key studies evaluating PELNs from diverse plant sources in preclinical models of osteoporosis (OP) and osteoarthritis (OA). It highlights disease models, major findings, and proposed molecular mechanisms, including modulation of osteoblast/osteoclast activity, BMSC differentiation, anti-inflammatory effects, and chondrocyte regeneration. Studies are categorized by disease focus (OP or OA) and include references to experimental outcomes and signaling pathways.
5. Therapeutic effects of exosome-like nanovesicles of plant origin in osteoarthritis
Osteoarthritis (OA) is a prevalent degenerative disease affecting the bones and joints, primarily occurring in middle-aged and elderly individuals. The pathology of OA encompasses the entire joint, with lesions affecting the joint capsule, synovium, cartilage, subchondral bone, menisci, ligaments, and muscles. [69] These alterations result in localized pain, swelling, stiffness, and potential complications such as joint dysfunction and deformation [70,71]. OA exhibits multifaceted pathological mechanisms, including necrosis of synovial and chondrocyte cells, inflammatory responses, degradation of the extracellular matrix, cellular dysfunction, and impaired autophagy [72–75]. The pathogenesis of OA is complex and is primarily associated with factors such as age, genetics, trauma, obesity, and others. Currently, the clinical management of OA remains a significant challenge. Recent studies have indicated that PELNs possess the ability to regulate immune responses, inhibit inflammation, and promote soft tissue regeneration, which collectively may alleviate the symptoms of OA and warrant further investigation.
5.1. PELN inhibits the inflammatory response
The inflammatory response is a significant pathological mechanism in osteoarthritis (OA) [76–79]. It has been observed that certain PELNs exhibit excellent anti-inflammatory activity [80]. A study conducted by Kim [81] found that ginseng-derived PELNs could exert anti-inflammatory effects by inhibiting the activation of NF-κB, thereby reducing the levels of inflammatory factors such as tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6). Zhu et al. [82] discovered that PELNs derived from garlic have the potential to protect the colon against DSS-induced damage by inhibiting the TLR4/MyD88/NF-κB signaling pathway and regulating gut microbiota. Vanessa’s study [83] demonstrated that goldberry-derived PELNs reduced the production of M1 macrophage products (e.g. NO) and promoted the polarization of M2 macrophages, thereby alleviating chronic inflammation in the body. Emmanuela’s research [84] indicated that PELNs sourced from Nigella sativa berries significantly decreased the expression of the IL-6 gene in cells, highlighting their important anti-inflammatory activity. Additionally, Iriawati [85] found that papaya-derived PELNs possess anti-inflammatory potential by upregulating the relative expression of anti-inflammatory cytokines such as IL-10 while downregulating pro-inflammatory cytokines such as IL-6 and IL-1β. A study by Wei [86] reported that turmeric-derived PELNs were enriched in curcumin and curcumin synthase, with the expression of curcumin synthase 2 being significantly higher than that in turmeric plant rhizomes. Curcumin has been shown to reduce the inflammatory response in OA and alleviate OA symptoms by inhibiting the activation of NF-κB, interleukin 8 (IL-8), nitric oxide synthase (NOS), prostaglandin E2 (PGE2), and cyclooxygenase-2 (COX-2) [87–90].
5.2. PELN promotes cartilage regeneration
Progressive degeneration and lysis of articular cartilage are hallmark features of osteoarthritis (OA) [91]. It has been found that miRNAs derived from plant-derived PELNs can regulate the plasticity of surviving cells at the injury site and modulate the extracellular matrix (ECM) to initiate cellular differentiation, proliferation, and tissue regeneration, thereby facilitating articular cartilage repair [92,93]. Yıldırım’s study [94] demonstrated that tomato-derived PELNs enhanced the expression of chondrocyte markers, including aggregated proteoglycan (ACAN), sex-determining region Y-framing protein 9 (SOX9), and cartilage oligomeric matrix protein (COMP), promoting cartilage regeneration. The study also revealed that PELNs could deliver growth factors to chondrocytes, contributing to the formation of a microenvironment conducive to cartilage regeneration and promoting the growth and maturation of new cartilage tissue. In a study by Chen et al. [95], after encapsulating spinach-derived nanocyst-like units (NTUs) with chondrocyte membranes (CM) and incorporating them into chondrocytes, it was found that CM-NTUs increased intracellular levels of ATP and nicotinamide adenine dinucleotide phosphate (NADPH), enhancing anabolic metabolism in degraded chondrocytes when exposed to natural light. This led to improved cartilage homeostasis and helped prevent the pathological progression of OA.
6. Quality assessment of existing recommendations
6.1. Current therapeutic frameworks and limitations
Current clinical guidelines for osteoporosis (OP) and osteoarthritis (OA) management rely on pharmacological and non-pharmacological interventions, yet exhibit significant limitations:
OP Therapies: Bisphosphonates (e.g. alendronate) and Selective Estrogen Receptor Modulators (SERMs; e.g. raloxifene) reduce fracture risk but carry long-term risks of atypical femoral fractures, osteonecrosis of the jaw, and gastrointestinal toxicity [45,49]. Parathyroid Hormone Analogs (e.g. teriparatide) promote bone formation but are limited by high cost, short-term use (≤24 months), and potential osteosarcoma risk [45]. Foundation Therapies (calcium/vitamin D) show modest efficacy in severe OP and poor adherence due to dosing frequency [6].
OA Therapies: NSAIDs (e.g. celecoxib) alleviate pain but accelerate cartilage degradation and pose renal/cardiovascular risks with chronic use [76,77]. Intra-articular Injections (corticosteroids/hyaluronic acid) offer transient symptom relief but may suppress cartilage matrix synthesis and fail to modify disease progression [73,75].
Most drugs lack tissue-targeted delivery, causing systemic side effects. Monotherapeutics inadequately address OP/OA complexity (e.g. OP involves osteoblast-osteoclast imbalance, inflammation, and oxidative stress [45,74]). Daily dosing regimens (e.g. bisphosphonates) reduce compliance [45] (Table 2).
Table 2.
Limitations of current pharmacological interventions for osteoporosis and osteoarthritis.
| Disease | Therapy category | Representative agents | Mechanism of action | Key limitations |
|---|---|---|---|---|
| OP | Bone Resorption Inhibitors | Bisphosphonates (e.g., Alendronate) | Induce osteoclast apoptosis | Atypical femoral fractures Osteonecrosis of jaw GI toxicity |
| Selective Estrogen Modulators | Raloxifene | Bind to estrogen receptors | Increased thromboembolism risk, Limited efficacy in severe OP |
|
| Bone Formation Promoters | Teriparatide (PTH analog) | Stimulate osteoblast activity | Osteosarcoma risk (animal models) ≤24-month use limit High cost |
|
| Foundation Therapies | Calcium/Vitamin D | Support mineral homeostasis | Poor adherence (daily dosing) Minimal benefit in advanced OP |
|
| OA | Oral Symptom Modifiers | NSAIDs (e.g., Celecoxib) | Inhibit COX-1/2 enzymes | Accelerated cartilage degradation Renal/CV risks (↑30% with chronic use) |
| Injectable Agents | Corticosteroids | Suppress synovial inflammation | Transient relief (≤4 weeks) Cartilage matrix suppression |
|
| Hyaluronic Acid | Enhance joint lubrication | Limited structural improvement Variable efficacy across patients |
6.2. PELNs as a strategic alternative to address limitations
PELNs demonstrate unique advantages over conventional therapies through multi-targeted actions:
Enhanced Safety Profile: Plant-derived lipids (e.g. phosphatidylcholine) confer biocompatibility without cytotoxic effects, contrasting with synthetic drug carriers [28,41]. Natural anti-inflammatory cargo (e.g. curcumin in turmeric PELNs) reduces OA inflammation without NSAID-related toxicity [86,88].
Multi-Pathway Modulation: For OP: Ginseng PELNs simultaneously suppress RANKL-induced osteoclastogenesis and activate BMP-2/RUNX2 osteogenic pathways, outperforming single-target drugs [54,57]. For OA: Tomato PELNs deliver growth factors (e.g. SOX9) to stimulate cartilage regeneration while inhibiting NF-κB-driven inflammation [94].
Surface proteins (e.g. HSP70) may enable selective bone homing, akin to animal exosomes [40,96], minimizing off-target effects (Table 2).
7. Conclusion
Osteoporosis (OP) and osteoarthritis (OA) are prevalent chronic skeletal disorders. Extensive studies have shown that traditional Chinese medicine (TCM) can regulate bone metabolism, reduce chronic inflammation in the body and promote cartilage regeneration, which is an effective treatment for osteoporosis and osteoarthritis, but the mechanism is still unclear. Structurally and functionally analogous to animal-derived exosomes, PELNs demonstrate broad regulatory effects on osteoclasts, osteoblasts, and bone marrow mesenchymal stem cells (BMSCs), enhance chondrocyte regeneration, and exhibit anti-inflammatory activity, suggesting their potential as a therapeutic mechanism of traditional Chinese medicine (TCM) in mitigating osteoporosis and delaying osteoarthritis progression. Notably, PELNs exhibit wider biological origins and superior scalability for large-scale production compared to animal exosomes.PELNs are similar to exosomes from animal cell sources in structure and function, and have a wider source and easier mass production than animal exosomes, which is expected to be a new approach for the treatment of osteoporosis and osteoarthritis in the future, but there are still a few issues that deserve attention.
Plant species, growth age, cultivation environment, and tissue sampling sites significantly influence PELNs properties [25]. Thus, standardized sourcing criteria for PELNs derived from identical plant species must be established. For functional studies of herbal PELNs, priority should be given to locally sourced herbs with defined growth environments, maturation periods, and consistent therapeutic efficacy to enhance experimental reproducibility. Additionally, PELNs characteristics are affected by isolation, purification, and characterization methodologies. A unified technical system for the separation and purification of PELNs should be established as soon as possible, and the specific markers of PELNs should be clarified. In addition, the medicinal properties of traditional Chinese medicine are affected by the method of concoction, and whether the method of concoction affects the function of extracellular vesicles secreted by plants of medicinal origin needs to be clarified by further research.
Similar to animal-derived exosomes, it is the contents of PELNs that play biological roles. Comprehensive lipidomic, transcriptomic, proteomic, and metabolomic profiling using multi-omics technologies with multi-parametric assessment is essential for identifying herbal vesicle biomarkers, evaluating PELNs’ therapeutic value, and facilitating translational applications. However, OP and OA pathological mechanisms are more complex, involving various factors such as aging, inflammation, and hormones. While existing studies suggest PELNs modulate osteoblast/chondrocyte differentiation and immune cell function, research has predominantly focused on phenotypic outcomes in bone metabolism and immunomodulation. The specific mechanisms underlying PELNs’ cross-species regulation of bone metabolism remain underexplored and require further elucidation.
Previous studies indicate that PELNs from different plant sources exert distinct biological effects. This warrants investigation into whether synergistic applications of multi-source PELNs, guided by TCM theory, could enhance efficacy while reducing toxicity. Finally, exosomal targeting capability is critical for maximizing therapeutic effects and minimizing adverse reactions. Although some animal-derived exosomes exhibit bone-targeting properties [96,97] and whether different PELNs have similar bone targeting properties needs to be confirmed by a large number of experiments. If highly bone-targeting PELNs can be identified, it is expected that PELNs will be utilized to develop new drugs with bone-targeting properties in the future.
Acknowledgments
[XTX, JGZ, XXX] carried out the investigation, and drafted the original manuscript. [WMW, RZ, KW] reviewed and edited the manuscript and created the visualizations presented in the article. [HQH, YHQ, ZWL] designed and modified the figure and captions. [FX, ZJP, QW] provided the funding, idea, and organization of this manuscript. All authors have read and approved the final manuscript.
Funding Statement
The current work was supported by National Clinical Research Base of Traditional Chinese Medicine Open Project (JD2023SZ23). Suzhou Science and Education Promoting Health Youth Science and Technology Project(KJXW2023077). Kunshan Chinese Medicine Science and Technology Development Special Project (KZYY2202).
Author contributions statement
CRediT: Xianting Xia: Investigation, Writing – original draft; Jinguo Zhu: Investigation, Writing – original draft; Xuexin Xu: Investigation, Writing – original draft; Weiming Wang: Visualization, Writing – review & editing; Rui Zhao: Visualization, Writing – review & editing; Kai Wu: Visualization, Writing – review & editing; Haoqiang Huang: Data curation, Formal analysis; Yinhua Qian: Data curation, Formal analysis; Zhiwen Luo: Data curation, Formal analysis; Feng Xu: Conceptualization, Funding acquisition, Project administration; Zhijian Peng: Conceptualization, Funding acquisition, Project administration; Qing Wang: Conceptualization, Funding acquisition, Project administration.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Literature screening methodology
The articles were selected with a narrative review.
Data availability statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1.Lane JM, Russell L, Khan SN.. Osteoporosis. Clin Orthop Relat Res. 2000;372(372):139–150. doi: 10.1097/00003086-200003000-00016. [DOI] [PubMed] [Google Scholar]
- 2.Rosen CJ, Feingold KR, Anawalt B, et al. The epidemiology and pathogenesis of osteoporosis. Endotext. South Dartmouth (MA): MDText.com, Inc; 2000. [Google Scholar]
- 3.Liu F, Wang X, He Y, et al. Jaw osteoporosis: challenges to oral health and emerging perspectives of treatment. Biomedicine & Pharmacotherapy. 2024;177:116995. doi: 10.1016/j.biopha.2024.116995. [DOI] [PubMed] [Google Scholar]
- 4.Liu R, Xu L-X, Tong L-J, et al. Therapeutic effects of ginsenosides on osteoporosis for novel drug applications. Eur J Pharmacol. 2024;974:176604. doi: 10.1016/j.ejphar.2024.176604. [DOI] [PubMed] [Google Scholar]
- 5.Steinmetz JD, Culbreth GT, Haile LM, et al. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508–e22. doi: 10.1016/S2665-9913(23)00163-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Srivastava M, Deal C.. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med. 2002;18(3):529–555. doi: 10.1016/s0749-0690(02)00022-8. [DOI] [PubMed] [Google Scholar]
- 7.Chen YJ, Jia LH, Han TH, et al. Osteoporosis treatment: current drugs and future developments. Front Pharmacol. 2024;15:1456796. doi: 10.3389/fphar.2024.1456796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Liang L, Wang N, Li X, et al. Shape engineering of exosomes for endoplasmic reticulum-targeted delivery and amplified anticancer efficacy. Nano Today. 2024;57:102377. doi: 10.1016/j.nantod.2024.102377. [DOI] [Google Scholar]
- 9.Mohammadi AH, Bagheri F, Baghaei K.. Chondroitin sulfate-tocopherol succinate modified exosomes for targeted drug delivery to CD44-positive cancer cells. Int J Biol Macromol. 2024;275(Pt 2):133625. doi: 10.1016/j.ijbiomac.2024.133625. [DOI] [PubMed] [Google Scholar]
- 10.Dowaidar M. Drug delivery based exosomes uptake pathways. Neurochem Int. 2024;179:105835. doi: 10.1016/j.neuint.2024.105835. [DOI] [PubMed] [Google Scholar]
- 11.U Stotz H, Brotherton D, Inal J.. Communication is key: extracellular vesicles as mediators of infection and defence during host-microbe interactions in animals and plants. FEMS Microbiol Rev. 2022;46(1):1–18. doi: 10.1093/femsre/fuab044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Kalluri R, Lebleu VS.. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478): 6478–6517. doi: 10.1126/science.aau6977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Zhang Y, Liu Y, Liu H, et al. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9(1):19. doi: 10.1186/s13578-019-0282-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Liang Y, Duan L, Lu J, et al. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183–3195. doi: 10.7150/thno.52570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.DEL Pozo-Acebo L, LóPEZ DE LAS Hazas MC, MARGOLLéS A, et al. Eating microRNAs: pharmacological opportunities for cross-kingdom regulation and implications in host gene and gut microbiota modulation. Br J Pharmacol. 2021;178(11):2218–2245. doi: 10.1111/bph.15421. [DOI] [PubMed] [Google Scholar]
- 16.Mu N, Li J, Zeng L, et al. Plant-derived exosome-like nanovesicles: current progress and prospects. Int J Nanomedicine. 2023;18:4987–5009. doi: 10.2147/IJN.S420748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Bai C, Liu J, Zhang X, et al. Research status and challenges of plant-derived exosome-like nanoparticles. Biomedicine & Pharmacotherapy. 2024;174:116543. doi: 10.1016/j.biopha.2024.116543. [DOI] [PubMed] [Google Scholar]
- 18.Yang C, Zhang M, Merlin D.. Advances in plant-derived edible nanoparticle-based lipid nano-drug delivery systems as therapeutic nanomedicines. J Mater Chem B. 2018;6(9):1312–1321. doi: 10.1039/C7TB03207B. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Rome S. Biological properties of plant-derived extracellular vesicles. Food Funct. 2019;10(2):529–538. doi: 10.1039/c8fo02295j. [DOI] [PubMed] [Google Scholar]
- 20.Zhang M, Viennois E, Xu C, et al. Plant derived edible nanoparticles as a new therapeutic approach against diseases. Tissue Barriers. 2016;4(2):e1134415. doi: 10.1080/21688370.2015.1134415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Jimenez-Jimenez S, Hashimoto K, Santana O, et al. Emerging roles of tetraspanins in plant inter-cellular and inter-kingdom communication. Plant Signal Behav. 2019;14(4):e1581559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Cong M, Tan S, Li S, et al. Technology insight: plant-derived vesicles-How far from the clinical biotherapeutics and therapeutic drug carriers?. Adv Drug Deliv Rev. 2022;182:114108. doi: 10.1016/j.addr.2021.114108. [DOI] [PubMed] [Google Scholar]
- 23.Kim J, Li S, Zhang S, et al. Plant-derived exosome-like nanoparticles and their therapeutic activities. Asian J Pharm Sci. 2022;17(1):53–69. doi: 10.1016/j.ajps.2021.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wang J, Ding Y, Wang J, et al. EXPO, an exocyst-positive organelle distinct from multivesicular endosomes and autophagosomes, mediates cytosol to cell wall exocytosis in Arabidopsis and tobacco cells. Plant Cell. 2010;22(12):4009–4030. doi: 10.1105/tpc.110.080697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Cui Y, Gao J, He Y, et al. Plant extracellular vesicles. Protoplasma. 2020;257(1):3–12. doi: 10.1007/s00709-019-01435-6. [DOI] [PubMed] [Google Scholar]
- 26.Subha D, Harshnii K, Madhikiruba KG, et al. Plant derived exosome- like Nanovesicles: an updated overview. Plant Nano Biology. 2023;3:100022. doi: 10.1016/j.plana.2022.100022. [DOI] [Google Scholar]
- 27.Suharta S, Barlian A, Hidajah AC, et al. Plant-derived exosome-like nanoparticles: a concise review on its extraction methods, content, bioactivities, and potential as functional food ingredient. J Food Sci. 2021;86(7):2838–2850. doi: 10.1111/1750-3841.15787. [DOI] [PubMed] [Google Scholar]
- 28.Yi Q, Xu Z, Thakur A, et al. Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment. Pharmacol Res. 2023;190:106733. doi: 10.1016/j.phrs.2023.106733. [DOI] [PubMed] [Google Scholar]
- 29.Liu Y, Ren C, Zhan R, et al. Exploring the potential of plant-derived exosome-like nanovesicle as functional food components for human health: a review. Foods. 2024;13(5). doi: 10.3390/foods13050712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.DI Gioia S, Hossain MN, Conese M.. Biological properties and therapeutic effects of plant-derived nanovesicles. Open Med (Wars). 2020;15(1):1096–1122. doi: 10.1515/med-2020-0160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Jin Z, NA J, Lin X, et al. Plant-derived exosome-like nanovesicles: a novel nanotool for disease therapy. Heliyon. 2024;10(9):e30630. doi: 10.1016/j.heliyon.2024.e30630. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xu K, Jin Y, Li Y, et al. Recent progress of exosome isolation and peptide recognition-guided strategies for exosome research. Front Chem. 2022;10:844124. doi: 10.3389/fchem.2022.844124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Bai C, Liu J, Zhang X, et al. Research status and challenges of plant-derived exosome-like nanoparticles. Biomed Pharmacother. 2024;174:116543. doi: 10.1016/j.biopha.2024.116543. [DOI] [PubMed] [Google Scholar]
- 34.MARTíNEZ-Greene JA, HERNáNDEZ-Ortega K, Quiroz-Baez R, et al. Quantitative proteomic analysis of extracellular vesicle subgroups isolated by an optimized method combining polymer-based precipitation and size exclusion chromatography. J Extracell Vesicles. 2021;10(6):e12087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Jackson KK, Powell RR, Bruce TF, et al. Solid-phase extraction of exosomes from diverse matrices via a polyester capillary-channeled polymer (C-CP) fiber stationary phase in a spin-down tip format]. Anal Bioanal Chem. 2020;412(19):4713–4724. doi: 10.1007/s00216-020-02728-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Marcus RK, Davis WC, Knippel BC, et al. Capillary-channeled polymer fibers as stationary phases in liquid chromatography separations. J Chromatogr A. 2003;986(1):17–31. doi: 10.1016/s0021-9673(02)01835-6. [DOI] [PubMed] [Google Scholar]
- 37.Zhao Q, Liu G, Liu F, et al. An enzyme-based system for extraction of small extracellular vesicles from plants. Sci Rep. 2023;13(1):13931. doi: 10.1038/s41598-023-41224-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Mao X, Li T, Qi W, et al. Advances in the study of plant-derived extracellular vesicles in the skeletal muscle system. Pharmacol Res. 2024;204:107202. [DOI] [PubMed] [Google Scholar]
- 39.THéRY C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. doi: 10.1080/20013078.2018.1535750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Pinedo M, DE LA Canal L, DE Marcos Lousa C.. A call for Rigor and standardization in plant extracellular vesicle research. J Extracell Vesicles. 2021;10(6):e12048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Iravani S, Varma RS.. Plant-derived edible nanoparticles and miRNAs: emerging frontier for therapeutics and targeted drug-delivery. ACS Sustainable Chem. Eng. 2019;7(9):8055–8069. doi: 10.1021/acssuschemeng.9b00954. [DOI] [Google Scholar]
- 42.Li S, Zhang R, Wang A, et al. Panax notoginseng: derived exosome-like nanoparticles attenuate ischemia reperfusion injury via altering microglia polarization. J Nanobiotechnology. 2023;21(1):416. doi: 10.1186/s12951-023-02161-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Jang J, Jeong H, Jang E, et al. Isolation of high-purity and high-stability exosomes from ginseng. Front Plant Sci. 2022;13:1064412. doi: 10.3389/fpls.2022.1064412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wu P, Wu W, Zhang S, et al. Therapeutic potential and pharmacological significance of extracellular vesicles derived from traditional medicinal plants. Front Pharmacol. 2023;14:1272241. doi: 10.3389/fphar.2023.1272241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Wang H, Luo Y, Wang H, et al. Mechanistic advances in osteoporosis and anti-osteoporosis therapies. MedComm (2020). 2023;4(3):e244. doi: 10.1002/mco2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Huo K L, Yang TY, Zhang WW, et al. Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment. World J Stem Cells. 2023;15(3):83–89. doi: 10.4252/wjsc.v15.i3.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Heidari N, Abbasi-Kenarsari H, Namaki S, et al. Adipose-derived mesenchymal stem cell-secreted exosome alleviates dextran sulfate sodium-induced acute colitis by Treg cell induction and inflammatory cytokine reduction. J Cell Physiol. 2021;236(8):5906–5920. doi: 10.1002/jcp.30275. [DOI] [PubMed] [Google Scholar]
- 48.Wei F, Li Z, Crawford R, et al. Immunoregulatory role of exosomes derived from differentiating mesenchymal stromal cells on inflammation and osteogenesis. J Tissue Eng Regen Med. 2019;13(11):1978–1991. doi: 10.1002/term.2947. [DOI] [PubMed] [Google Scholar]
- 49.Oryan A, Sahvieh S.. Effects of bisphosphonates on osteoporosis: focus on zoledronate. [Life Sci. 2021;264:118681. J doi: 10.1016/j.lfs.2020.118681. [DOI] [PubMed] [Google Scholar]
- 50.Pu H, Wen X, Luo D, et al. Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system. J Steroid Biochem Mol Biol. 2023;227:106199. doi: 10.1016/j.jsbmb.2022.106199. [DOI] [PubMed] [Google Scholar]
- 51.Takayanagi H. RANKL as the master regulator of osteoclast differentiation. J Bone Miner Metab. 2021;39(1):13–18. doi: 10.1007/s00774-020-01191-1. [DOI] [PubMed] [Google Scholar]
- 52.Kobayashi Y, Udagawa N, Takahashi N.. Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr. 2009;19(1):61–72. [DOI] [PubMed] [Google Scholar]
- 53.Takahashi N, Maeda K, Ishihara A, et al. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Front Biosci (Landmark Ed). 2011;16(1):21–30. doi: 10.2741/3673. [DOI] [PubMed] [Google Scholar]
- 54.Seo K, Yoo JH, Kim J, et al. Ginseng-derived exosome-like nanovesicles extracted by sucrose gradient ultracentrifugation to inhibit osteoclast differentiation. Nanoscale. 2023;15(12):5798–5808. doi: 10.1039/d2nr07018a. [DOI] [PubMed] [Google Scholar]
- 55.Park YS, Kim HW, Hwang JH, et al. Plum-derived exosome-like nanovesicles induce differentiation of osteoblasts and reduction of osteoclast activation. Nutrients. 2023;15(9):2107. doi: 10.3390/nu15092107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Ingwersen LC, Frank M, Naujokat H, et al. BMP-2 long-term stimulation of human pre-osteoblasts induces osteogenic differentiation and promotes transdifferentiation and bone remodeling processes. Int J Mol Sci. 2022;23(6):3077. doi: 10.3390/ijms23063077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Hwang JH, Park YS, Kim HS, et al. Yam-derived exosome-like nanovesicles stimulate osteoblast formation and prevent osteoporosis in mice. J Control Release. 2023;355:184–198. doi: 10.1016/j.jconrel.2023.01.071. [DOI] [PubMed] [Google Scholar]
- 58.Sim Y, Seo HJ, Kim DH, et al. The effect of apple-derived nanovesicles on the osteoblastogenesis of osteoblastic MC3T3-E1 cells. J Med Food. 2023;26(1):49–58. doi: 10.1089/jmf.2022.K.0094. [DOI] [PubMed] [Google Scholar]
- 59.Cao Y, Tan X, Shen J, et al. Morinda Officinalis-derived extracellular vesicle-like particles: anti-osteoporosis effect by regulating MAPK signaling pathway. Phytomedicine. 2024;129:155628. doi: 10.1016/j.phymed.2024.155628. [DOI] [PubMed] [Google Scholar]
- 60.Chen Q, Shou P, Zheng C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?. Cell Death Differ. 2016;23(7):1128–1139. doi: 10.1038/cdd.2015.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Hu L, Yin C, Zhao F, et al. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. Int J Mol Sci. 2018;19(2). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23(9):1072–1079. doi: 10.1038/nm.4385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Shen J, Tsai YT, Dimarco NM, et al. Transplantation of mesenchymal stem cells from young donors delays aging in mice. Sci Rep. 2011;1(1):67. doi: 10.1038/srep00067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Qadir A, Liang S, Wu Z, et al. Senile osteoporosis: the involvement of differentiation and senescence of bone marrow stromal cells. Int J Mol Sci. 2020;21(1):349. doi: 10.3390/ijms21010349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Zhao Q, Feng J, Liu F, et al. Rhizoma Drynariae-derived nanovesicles reverse osteoporosis by potentiating osteogenic differentiation of human bone marrow mesenchymal stem cells via targeting ERα signaling. Acta Pharm Sin B. 2024;14(5):2210–2227. doi: 10.1016/j.apsb.2024.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Zhan W, Deng M, Huang X, et al. Pueraria lobata-derived exosome-like nanovesicles alleviate osteoporosis by enhacning autophagy. J Control Release. 2023;364:644–653. doi: 10.1016/j.jconrel.2023.11.020. [DOI] [PubMed] [Google Scholar]
- 67.Perut F, Roncuzzi L, Avnet S, et al. Strawberry-derived exosome-like nanoparticles prevent oxidative stress in human mesenchymal stromal cells. Biomolecules. 2021;11(1). doi: 10.3390/biom11010087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Gupta R, Gupta S, Gupta P, et al. Establishing the callus-based isolation of extracellular vesicles from cissus quadrangularis and elucidating their role in osteogenic differentiation. J Funct Biomater. 2023;14(11):540. doi: 10.3390/jfb14110540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Cucchiarini M, DE Girolamo L, Filardo G, et al. Basic science of osteoarthritis. J Exp Orthop. 2016;3(1):22. doi: 10.1186/s40634-016-0060-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Ratneswaran A, Kapoor M.. Osteoarthritis year in review: genetics, genomics, epigenetics. Osteoarthritis Cartilage. 2021;29(2):151–160. doi: 10.1016/j.joca.2020.11.003. [DOI] [PubMed] [Google Scholar]
- 71.Riggs KC, Sankar U.. Inflammatory mechanisms in post-traumatic osteoarthritis: a role for CaMKK2. Immunometabolism (Cobham). 2023;5(4):e00031. doi: 10.1097/IN9.0000000000000031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Roelofs AJ, DE Bari C.. Osteoarthritis year in review 2023: biology. Osteoarthritis Cartilage. 2024;32(2):148–158. doi: 10.1016/j.joca.2023.11.002. [DOI] [PubMed] [Google Scholar]
- 73.Muratovic D, Atkins GJ, Findlay DM.. Is RANKL a potential molecular target in osteoarthritis?. Osteoarthritis Cartilage. 2024;32(5):493–500. doi: 10.1016/j.joca.2023.10.010. [DOI] [PubMed] [Google Scholar]
- 74.Mccreery KP, Xu X, Scott AK, et al. Nuclear stiffness decreases with disruption of the extracellular matrix in living tissues. Small. 2021;17(6):e2006699. doi: 10.1002/smll.202006699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Zhao T, Li X, Li H, et al. Advancing drug delivery to articular cartilage: from single to multiple strategies. Acta Pharm Sin B. 2023;13(10):4127–4148. doi: 10.1016/j.apsb.2022.11.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(1):16–21. [DOI] [PubMed] [Google Scholar]
- 77.Chow YY, Chin KY.. The role of inflammation in the pathogenesis of osteoarthritis. Mediators Inflamm. 2020;2020:8293921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Hedbom E, HäUSELMANN HJ.. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci. 2002;59(1):45–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Urban H, Little CB.. The role of fat and inflammation in the pathogenesis and management of osteoarthritis. Rheumatology (Oxford). 2018;57(suppl_4):iv10–iv21. doi: 10.1093/rheumatology/kex399. [DOI] [PubMed] [Google Scholar]
- 80.Li DF, Tang Q, Yang MF, et al. Plant-derived exosomal nanoparticles: potential therapeutic for inflammatory bowel disease. Nanoscale Adv. 2023;5(14):3575–3588. doi: 10.1039/d3na00093a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Kim J, Zhang S, Zhu Y, et al. Amelioration of colitis progression by ginseng-derived exosome-like nanoparticles through suppression of inflammatory cytokines. J Ginseng Res. 2023;47(5):627–637. doi: 10.1016/j.jgr.2023.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Zhu Z, Liao L, Gao M, et al. Garlic-derived exosome-like nanovesicles alleviate dextran sulphate sodium-induced mouse colitis via the TLR4/MyD88/NF-κB pathway and gut microbiota modulation. Food Funct. 2023;14(16):7520–7534. doi: 10.1039/d3fo01094e. [DOI] [PubMed] [Google Scholar]
- 83.Vanessa V, Rachmawati H, Barlian A.. Anti-inflammatory potential of goldenberry-derived exosome-like nanoparticles in macrophage polarization. Future Sci OA. 2024;10(1):Fso943. doi: 10.2144/fsoa-2023-0172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Emmanuela N, Muhammad DR, Wijaya CH, et al. Isolation of plant-derived exosome-like nanoparticles (PDENs) from Solanum nigrum L. berries and Their Effect on interleukin-6 expression as a potential anti-inflammatory agent. PLoS One, 2024, 19(1): e0296259. doi: 10.1371/journal.pone.0296259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Iriawati I, Vitasasti S, Rahmadian F N A, et al. Isolation and characterization of plant-derived exosome-like nanoparticles from Carica papaya L. fruit and their potential as anti-inflammatory agent. PLoS One. 2024;19(7):e0304335. doi: 10.1371/journal.pone.0304335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Wei Y, Cai X, Wu Q, et al. Extraction, isolation, and component analysis of turmeric-derived exosome-like nanoparticles. Bioengineering (Basel). 2023;10(10) doi: 10.3390/bioengineering10101199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Qiu B, Xu X, Yi P, et al. Curcumin reinforces MSC-derived exosomes in attenuating osteoarthritis via modulating the miR-124/NF-kB and miR-143/ROCK1/TLR9 signalling pathways. J Cell Mol Med. 2020;24(18):10855–10865. doi: 10.1111/jcmm.15714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Henrotin Y, Gharbi M, Dierckxsens Y, et al. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med. 2014;14(1):159. doi: 10.1186/1472-6882-14-159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Ghasemi F, Shafiee M, Banikazemi Z, et al. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol Res Pract. 2019;215(10):152556. doi: 10.1016/j.prp.2019.152556. [DOI] [PubMed] [Google Scholar]
- 90.Katsori AM, Palagani A, Bougarne N, et al. Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue. Molecules. 2015;20(1):863–878. doi: 10.3390/molecules20010863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Rim YA, Nam Y, Ju JH.. The role of chondrocyte hypertrophy and senescence in osteoarthritis initiation and progression. Int J Mol Sci. 2020;21(7):2358. doi: 10.3390/ijms21072358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Sen CK, Ghatak S.. miRNA control of tissue repair and regeneration. Am J Pathol. 2015;185(10):2629–2640. doi: 10.1016/j.ajpath.2015.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Sarasati A, Syahruddin MH, Nuryanti A, et al. Plant-derived exosome-like nanoparticles for biomedical applications and regenerative therapy. Biomedicines. 2023;11(4):1053. doi: 10.3390/biomedicines11041053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.YıLDıRıM M, Ünsal N, Kabataş B, et al. Effect of Solanum lycopersicum and Citrus limon-derived exosome-like vesicles on chondrogenic differentiation of adipose-derived stem cells. Appl Biochem Biotechnol. 2024;196(1):203–219. J doi: 10.1007/s12010-023-04491-0. [DOI] [PubMed] [Google Scholar]
- 95.Chen P, Liu X, Gu C, et al. A plant-derived natural photosynthetic system for improving cell anabolism. Nature. 2022;612(7940):546–554. doi: 10.1038/s41586-022-05499-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Huang H, Feng X, Feng Y, et al. Bone-targeting HUVEC-derived exosomes containing miR-503-5p for osteoporosis therapy. ACS Appl Nano Mater. 2024;7(1):1156–1169. doi: 10.1021/acsanm.3c05056. [DOI] [Google Scholar]
- 97.Song H, Li X, Zhao Z, et al. Reversal of osteoporotic activity by endothelial cell-secreted bone targeting and biocompatible exosomes. Nano Lett. 2019;19(5):3040–3048. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.


